Effects of Potent Antiretroviral Therapy on Kaposi's Sarcoma
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Background:
Kaposi's sarcoma (KS) is caused by a gammaherpesvirus called Kaposi's sarcoma-associated herpesvirus (KSHV), or human herpesvirus-8 (HHV-8). However, infection with KSHV is not sufficient to cause KS, and HIV infection is an important cofactor. Treatment of HIV with potent antiretroviral therapy can reduce the risk of KS, and can also induce regression in patients with established HIV-KS. One mechanism by which HIV is believed to contribute to KS is through HIV-induced immunodeficiency which leads to a loss of immunologic control of KSHV and/or KS itself. However, other mechanisms may also contribute.
Objectives:
One primary objective is to assess the effects of the initiation of potent anti-HIV therapy on specific factors possibly linked to the control or pathogenesis of KS, namely serum viral IL-6 and plasma VEGF levels, in patients with KS or at risk for KS by virtue of being infected with KSHV/HHV-8. Another is to assess the effects of anti-HIV therapy on KSHV infection. Secondary objectives are to assess the effects of potent antiretroviral therapy on established KS and other factors related to KS or KSHV infection.
Eligibility:
The principal eligibility factors are age 13 or above, HIV infection, and either KS or infection with KSHV. Exclusion factors include KS that requires specific therapy, recent corticosteroid therapy, recent cytokine therapy, or opportunistic infections requiring therapy.
Design:
Patients will be treated with potent antiretroviral therapy. For patients with established KS, the effects of the therapy on the KS will be monitored. In addition, a variety of factors related to KS, HIV infection, therapy, or KSHV infection will be monitored. These include the HIV viral load, KSHV secretion in saliva, the CD4 count, serum VEGF levels, and serum IL-6 levels.
Condition |
---|
HIV Seropositivity Kaposi's Sarcoma HIV Infections |
Study Type: | Observational |
Official Title: | A Study of the Effects of Potent Anti-HIV Therapy on Parameters Hypothesized to be Related to the Pathogenesis of Kaposi's Sarcoma (KS) in HIV-Infected Individuals |
Enrollment: | 24 |
Study Start Date: | August 2000 |
Estimated Study Completion Date: | June 2012 |
Background:
Kaposi's sarcoma (KS) is caused by a gammaherpesvirus called Kaposi's sarcoma-associated herpesvirus (KSHV), or human herpesvirus-8 (HHV-8). However, infection with KSHV is not sufficient to cause KS, and HIV infection is an important cofactor. Treatment of HIV with potent antiretroviral therapy can reduce the risk of KS, and can also induce regression in patients with established HIV-KS. One mechanism by which HIV is believed to contribute to KS is through HIV-induced immunodeficiency which leads to a loss of immunologic control of KSHV and/or KS itself. However, other mechanisms may also contribute.
Objectives:
One primary objective is to assess the effects of the initiation of potent anti-HIV therapy on specific factors possibly linked to the control or pathogenesis of KS, namely serum viral IL-6 and plasma VEGF levels, in patients with KS or at risk for KS by virtue of being infected with KSHV/HHV-8. Another is to assess the effects of anti-HIV therapy on KSHV infection. Secondary objectives are to assess the effects of potent antiretroviral therapy on established KS and other factors related to KS or KSHV infection.
Eligibility:
The principal eligibility factors are age 13 or above, HIV infection, and either KS or infection with KSHV. Exclusion factors include KS that requires specific therapy, recent corticosteroid therapy, recent cytokine therapy, or opportunistic infections requiring therapy.
Design:
Patients will be treated with potent antiretroviral therapy. For patients with established KS, the effects of the therapy on the KS will be monitored. In addition, a variety of factors related to KS, HIV infection, therapy, or KSHV infection will be monitored. These include the HIV viral load, KSHV secretion in saliva, the CD4 count, serum VEGF levels, and serum IL-6 levels.
Ages Eligible for Study: | 13 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
- INCLUSION CRITERIA:
Age greater than or equal to 13 years
HIV seropositive
Either a diagnosis of Kaposi's sarcoma and/or HHV-8/KSHV seropositive
EXCLUSION CRITERIA:
Requirement for specific anti-KS therapy
Specific anti-KS therapy within 4 weeks of study entry
Corticosteroid therapy within 4 weeks prior to initiating study
Condition that periodically requires immune suppressive therapy (e.g. asthma)
Cytokine therapy within 4 weeks of study entry
HIV-associated opportunistic complications requiring therapy
Inability to provide informed consent
Investigator recommendation that antiretroviral therapy is in best patient interest
Inability to comply with protocol
United States, Maryland | |
National Institutes of Health Clinical Center, 9000 Rockville Pike | |
Bethesda, Maryland, United States, 20892 |
Principal Investigator: | Kevin A Camphausen, M.D. | National Cancer Institute (NCI) |
Publications:
ClinicalTrials.gov Identifier: | NCT00006171 History of Changes |
Obsolete Identifiers: | NCT00020319 |
Other Study ID Numbers: | 000193, 00-C-0193 |
Study First Received: | August 10, 2000 |
Last Updated: | December 19, 2012 |
Health Authority: | United States: Federal Government |
Keywords provided by National Institutes of Health Clinical Center (CC):
HHV-8 Pathophysiology AIDS Cancer |
Anti-Retroviral Kaposi's Sarcoma HIV |
Additional relevant MeSH terms:
HIV Infections Acquired Immunodeficiency Syndrome HIV Seropositivity Sarcoma, Kaposi Sarcoma Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral |
Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Herpesviridae Infections DNA Virus Infections Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms Neoplasms, Vascular Tissue |
ClinicalTrials.gov processed this record on February 21, 2013